Can I Take Glutathione with Leqvio (Inclisiran)?

How Inclisiran Works at the Hepatocyte Level

Inclisiran is a first-in-class small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine (GalNAc), which directs uptake into hepatocytes via the asialoglycoprotein receptor (ASGPR). Once inside the cell, inclisiran binds PCSK9 messenger RNA and triggers its degradation through the RNA-induced silencing complex (RISC) [3]. This prevents PCSK9 protein from being secreted, which in turn allows more LDL receptors to recycle to the hepatocyte surface and clear LDL-C from the bloodstream.

Why CYP450 Is Not Involved

Unlike statins, ezetimibe, or PCSK9 monoclonal antibodies, inclisiran does not undergo phase I oxidative metabolism. The FDA prescribing label states that inclisiran is metabolized by nucleases, not cytochrome P450 isoenzymes [4]. This distinction matters because glutathione's primary metabolic pathway (conjugation via glutathione S-transferase) also sits outside the CYP450 system. Two agents that bypass the same enzymatic bottleneck are less likely to compete for clearance.

The ORION Trial Program

The ORION clinical program confirmed inclisiran's efficacy and tolerability across multiple populations. In ORION-10 (N=1,561 patients with atherosclerotic cardiovascular disease), inclisiran 284 mg subcutaneously reduced LDL-C by 52.3% at Day 510 compared with placebo (P<0.001) [1]. ORION-11 (N=1,617) showed similar results in a mixed ASCVD and familial hypercholesterolemia population, with a 49.9% LDL-C reduction [1]. Injection-site reactions occurred in 5% of inclisiran-treated patients; hepatotoxicity signals were rare.

How Glutathione Is Metabolized

Glutathione (GSH) is a tripeptide of glutamate, cysteine, and glycine. It is the body's most abundant intracellular antioxidant and plays a central role in phase II detoxification. The liver synthesizes approximately 80 to 85% of circulating glutathione, and hepatocytes maintain millimolar concentrations of GSH to neutralize reactive oxygen species and conjugate xenobiotics via the GST enzyme family [5].

Oral vs. Liposomal vs. IV Forms

Oral glutathione faces extensive first-pass hydrolysis by gamma-glutamyltransferase (GGT) in the gut and liver. A randomized controlled trial (N=54) published in the European Journal of Nutrition found that 1,000 mg/day of oral glutathione for 6 months raised blood GSH levels by 30 to 35% over baseline, though the clinical significance of this increase remains debated [2]. Liposomal formulations may improve absorption by encapsulating GSH in phospholipid vesicles. IV glutathione delivers the highest acute plasma concentrations but is not FDA-regulated as a drug and is administered off-label.

Phase II Conjugation and Inclisiran

Because inclisiran is a nucleotide-based molecule degraded by endonucleases and exonucleases rather than by conjugation reactions, supplemental glutathione does not compete for the same detoxification pathways. The GST system that processes glutathione conjugates handles electrophilic compounds (acetaminophen metabolites, environmental toxins), not siRNA duplexes. This is why the Natural Medicines Comprehensive Database does not list a glutathione-inclisiran interaction [6].

Is There a Pharmacodynamic Overlap?

A pharmacodynamic interaction would mean that glutathione changes the biological effect of inclisiran (or vice versa) even without affecting each other's blood levels.

Antioxidant Effects on LDL Metabolism

Oxidized LDL (oxLDL) is taken up by macrophage scavenger receptors and contributes to plaque formation. Glutathione, by reducing oxidative stress, may lower oxLDL levels. A 2013 meta-analysis of antioxidant supplementation and lipid profiles (17 RCTs, N=1,067) found a modest but statistically significant reduction in oxLDL with antioxidant use, though total LDL-C changes were inconsistent [7]. The Endocrine Society's 2020 lipid management guidelines do not recommend antioxidant supplements as LDL-lowering therapy [8].

Could Glutathione Blunt Inclisiran's Effect?

No evidence supports this concern. Inclisiran's mechanism (PCSK9 mRNA silencing) operates at the genetic transcription level inside the hepatocyte nucleus, upstream of any antioxidant-mediated changes to LDL oxidation state. Glutathione acts on already-circulating LDL particles. These are distinct physiological compartments.

Theoretical Hepatoprotective Benefit

Some clinicians speculate that glutathione supplementation may offer a hepatoprotective effect for patients on hepatocyte-targeted therapies. A 2017 study in patients with non-alcoholic fatty liver disease (N=34) found that oral glutathione (300 mg/day for 4 months) reduced ALT by a mean of 13.2 U/L compared with placebo [9]. Whether this translates to any benefit for inclisiran users, who rarely experience hepatotoxicity, is unknown.

Dose-Separation Windows and Practical Guidance

No published guideline or FDA document mandates separating glutathione from inclisiran by any specific time interval. This is consistent with the absence of a shared metabolic pathway.

Why Some Clinicians Still Recommend Spacing

The reasoning is precautionary, not evidence-based. Because both agents are processed by hepatocytes, a minority of prescribers suggest taking oral glutathione at least 2 hours apart from any hepatocyte-targeted therapy. This advice mirrors the general recommendation for separating supplements from medications with narrow therapeutic indices, a category that does not include inclisiran. The 2023 American College of Cardiology expert consensus on lipid-lowering therapy does not address supplement timing for siRNA-based drugs [10].

IV Glutathione Considerations

IV glutathione delivers supraphysiologic concentrations directly to the bloodstream. No pharmacokinetic study has evaluated concurrent IV glutathione and subcutaneous inclisiran. Because inclisiran is dosed only every 6 months (after two loading doses at Day 0 and Day 90), the window of potential concern is narrow. Peak plasma inclisiran concentrations occur approximately 4 hours after injection and decline rapidly as the drug is taken up by hepatocytes [4]. Scheduling IV glutathione infusions on non-injection days eliminates any theoretical overlap with peak inclisiran plasma levels.

Monitoring Recommendations

The ACC/AHA 2018 cholesterol guideline recommends checking a lipid panel 4 to 12 weeks after initiating or adjusting lipid-lowering therapy, then every 3 to 12 months thereafter [10]. The inclisiran prescribing information does not require routine liver-function testing, though baseline hepatic panel measurement is standard clinical practice.

Suggested Labs When Combining Both

For patients taking glutathione alongside inclisiran, a reasonable monitoring schedule includes:

• Baseline: comprehensive metabolic panel (CMP), lipid panel, LDL-C
• Week 4 to 12 after first inclisiran dose: repeat lipid panel, ALT, AST
• Every 6 months (coinciding with inclisiran dosing): lipid panel, hepatic function panel
• As needed: GGT if glutathione dose exceeds 1,000 mg/day or if IV glutathione is used

When to Alert Your Prescriber

Contact your prescriber if you develop right upper quadrant pain, unexplained fatigue, jaundice, or dark urine. These symptoms may indicate hepatic stress regardless of cause. A rise in ALT to more than 3 times the upper limit of normal warrants holding both the supplement and the medication pending evaluation.

What the Guidelines Say About Supplements and siRNA Therapy

The 2021 Endocrine Society clinical practice guideline on lipid management in endocrine disorders does not address glutathione specifically but notes that "dietary supplements with purported lipid-lowering effects should not replace evidence-based pharmacotherapy" [8]. The American Heart Association's 2019 scientific advisory on dietary supplements and cardiovascular disease concluded that most supplements lack sufficient evidence for routine recommendation [11].

Glutathione's Regulatory Status

Glutathione is classified as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA) of 1994. It is not subject to FDA premarket approval, and manufacturers are not required to demonstrate drug-interaction safety before sale. This regulatory gap means the absence of a documented interaction reflects the absence of systematic study, not a confirmed absence of risk.

ACC Expert Consensus on Novel Lipid Therapies

The 2023 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-C lowering lists inclisiran alongside PCSK9 monoclonal antibodies and bempedoic acid [12]. The document does not include supplement interaction guidance for any of these agents. Until dedicated interaction studies are performed, clinicians must rely on mechanistic reasoning and pharmacokinetic first principles.

Who Should Be Extra Cautious

Certain patient populations warrant closer monitoring when combining any hepatocyte-targeted drug with liver-processed supplements.

Patients with Pre-existing Liver Disease

Inclisiran was studied in patients with mild hepatic impairment (Child-Pugh A) in the ORION-8 open-label extension trial, with no significant safety signal [13]. Patients with moderate-to-severe hepatic impairment (Child-Pugh B or C) were excluded from most ORION trials. For these individuals, adding high-dose glutathione (particularly IV) introduces a variable that has not been studied in this context.

Patients on Statin/Ezetimibe Combination Therapy

Many inclisiran users are on concurrent statin therapy. Statins are metabolized by CYP3A4 (atorvastatin, lovastatin) or CYP2C9 (rosuvastatin, fluvastatin). Glutathione does not inhibit or induce these enzymes based on available in-vitro data [6]. The combination of inclisiran plus statin plus glutathione is therefore not expected to produce a three-way interaction, but no clinical study has tested this specific combination.

Immunocompromised Patients

Glutathione plays a role in T-cell function and immune regulation. A 2019 systematic review found that GSH depletion is associated with impaired lymphocyte proliferation [14]. Patients using glutathione for immune support who are simultaneously receiving inclisiran should inform both their immunologist and cardiologist.

The Bottom Line for Patients Already Taking Both

If you are already taking glutathione and have started Leqvio, no published evidence indicates you need to stop. Tell your prescriber about all supplements at your next visit. Request a hepatic function panel at baseline and at each 6-month inclisiran injection. If you use IV glutathione, schedule infusions at least 48 hours away from your inclisiran injection date to avoid any overlap with peak drug plasma levels.